Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04149860 · ClinicalTrials.gov registry record · Phase 1

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

A Phase 1 study, sponsored by H. Lundbeck A/S.

Completed
Registry status
Phase 1
Development phase
86
Enrollment target

NCT04149860: Completed Phase 1 study, sponsored by H. Lundbeck A/S.

NCT04149860 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04149860, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.

COMPLETED
Registry status
Phase 1
Development phase
86 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the safety of a single dose of Lu AF87908, how well it is tolerated and what the body does to the drug in healthy participants and participants with Alzheimer's disease.

Primary Outcome

Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)

Interventions

  • DRUG Placebo
  • DRUG Lu AF87908

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2019-09-27
Est. Completion 2023-07-19
Phase Phase 1
H. Lundbeck A/S

72 total trials

What the finished NCT04149860 record still lists

NCT04149860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04149860 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04149860 about?

NCT04149860 is a clinical study titled "Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease". The purpose of this study is to investigate the safety of a single dose of Lu AF87908, how well it is tolerated and what the body does to the drug in healthy participants and participants with Alzheimer's disease.

What is the current status of trial NCT04149860?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2019-09-27. Estimated completion is 2023-07-19.

What interventions are being tested in trial NCT04149860?

The interventions under investigation include: Placebo (DRUG), Lu AF87908 (DRUG).

Who is sponsoring clinical trial NCT04149860?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04149860's enrollment target sits among peer trials

86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04149860, the US trial registry maintained by the National Library of Medicine. NCT04149860 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.